OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
VANCOUVER, British Columbia, May 02, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming Deutsche Bank 43rd Annual Healthcare Conference in Boston on Wednesday, May 9th 2018.
Aquinox Presentation Details
Date: Wednesday, May 9th 2018
Time: 6:20 am Pacific Time / 9:20 am Eastern Time
Location: Boston, MA – Intercontinental Hotel Boston
A live webcast and archive of the event will be available at:
https://edge.media-server.com/m6/p/oiye7bcp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
